Dudediligence.

Ocugen, Inc

OCGNNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$1.1MSep ’24$764,000Dec ’24$1.5MMar ’25$1.4MJun ’25$1.8MSep ’25−$193,000Dec ’25$1.5MMar ’26$1.5MJun ’26
Net income, by quarter
−$13.0MSep ’24−$13.9MDec ’24−$15.3MMar ’25−$14.7MJun ’25−$20.1MSep ’25−$17.9MDec ’25−$19.2MMar ’26−$24.9MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$0.00$2.5M$6.0M$4.1M$4.4M
Operating income−$58.0M−$89.1M−$65.5M−$54.8M−$62.9M
Net income−$58.4M−$86.8M−$63.1M−$54.1M−$68.0M
Operating cash flow−$47.9M−$60.1M−$62.1M−$42.1M−$57.0M
Free cash flow−$48.9M−$64.5M−$72.5M−$45.5M−$57.1M
Cash$95.1M$77.6M$39.5M$58.8M$18.6M
Debt$1.7M$2.3M$2.8M$28.7M$28.8M
Shares outstanding199.4M221.6M256.6M291.4M312.4M
OCGN fundamentals · DudeDiligence